Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Inovio Pharmaceuticals (NYSEMKT:INO), Johnson & Johnson (NYSE:JNJ)

Pfizer Inc. (NYSE:PFE) announced encouraging top-line data from a phase IIIb study evaluating Genotropin for increasing height in small-for-gestational-age (SGA) children aged between 24 and 30 months. Pfizer Inc. (NYSE:PFE) stock performance was -0.25% in last session and finished the day at $32.10. Traded volume was 27.74million shares in the last session and the average volume of the stock remained 26.63million shares. The beta of the stock remained 0.67. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

Gilead Sciences, Inc. (NASDAQ:GILD) announced that the company’s Marketing Authorization Application,MAA, for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir, LDV, 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir, SOF, 400 mg for the treatment of chronic hepatitis C virus, HCV, genotype 1 infection, has been fully validated and is now under assessment by the European Medicines Agency, EMA. Gilead Sciences, Inc. (NASDAQ:GILD) dropped -1.88 percent to $71.41 Thursday on volume of 17.75million shares. The intra-day range of the stock was $70.59 to $73.34. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of $108.82billion.

Inovio Pharmaceuticals Inc (NYSE:INO) was up, gaining 10.53 percent to $3.57 after the company received the “Best Theraputic Vaccine” award at the World Vaccine Congress after the close Wednesday. Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s stock on Mar 27, 2014 reported a increase of 12.69% to the closing price of $3.64. Its fifty two weeks range is $0.49 -$3.95. The total market capitalization recorded $872.18million. The overall volume in the last trading session was 17.44million shares. In its share capital, INO has 208.86million outstanding shares.

Johnson & Johnson (NYSE:JNJ) had dismissed the destroyed documents as “inadvertent loss of certain, limited documents,” those fighting the company on the issue regarding pelvic implants accused of harming women have a different view. On Thursday, shares of Johnson & Johnson (NYSE:JNJ) advanced 0.24% to close the day at $97.28. Company return on investment (ROI) is 15.00% and its monthly performance is recorded as 6.77%. Johnson & Johnson (NYSE:JNJ) quarterly revenue growth is 6.43%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone